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Background: Patients with non-valvular atrial fibrillation (NVAF) are at enhanced risk of embolic stroke; it has been reported that up to 90% of left 
atrial thrombi in NVAF patients are found in the left atrial appendage (LAA).
Methods: The WATCHMAN LAA Closure device (Atritech, Plymouth, MN) is made of nitinol, incorporates fixation barbs around its perimeter and has 
a porous membrane on its atrial surface. A multi-center pilot study was initiated in August 2002. Patients were assessed at 45 days, 6 months and 
one year with transesophageal echo (TEE) and clinically assessed annually.
Results: Of 75 patients enrolled, the device was implanted successfully in 66. Anatomic limitations prevented implantation in 7, failure of venous 
access and an earlier generation delivery cable problem resulted in the other 2 unsuccessful implants. Mean follow up was 67±21 months for all 
patients and 80±9 months for patients still actively followed. Mean age was 68.5±8 years at enrollment. The acute results have been published 
previously. After 6 months, 92% had discontinued warfarin therapy and at the present time, 91% remain off warfarin therapy. On routine 6 month TEE 
follow-up, 4 patients were noted to have a thrombus layer along the atrial face of the implant, one of whom developed a transient ischemic attack 
(TIA). Warfarin was restarted in these patients for 3 months without further evidence of thrombus. Two patients had an embolic stroke; one at 2 
months and one at 39 months in the setting of severe concurrent carotid disease. These data reflect an actual stroke rate of 0.5% (2 events in 368 
patient years); the expected stroke rate given a mean CHADS2 Score of 1.8 ± 1.1 would have been 5.75%. Fourteen patients have died (mean 47± 
20 months), all deaths were non-device and non-procedure related.
Conclusions: The data suggest that WATCHMAN LAA Closure is safe and feasible, with two embolic strokes through more than 6 years of active 
follow up. A randomized study comparing the WATCHMAN device with warfarin for stroke prevention in NVAF is still ongoing.
